National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

yttrium Y 90 DOTA monoclonal antibody HuAFP31
A radioimmunoconjugate comprised of the monoclonal antibody HuAFP31, directed against alpha fetoprotein, that is conjugated to the chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and radiolabeled with the beta-emitting radioisotope Yttrium Y90. Yttrium Y 90 DOTA monoclonal antibody HuAFP31 binds to tumor cells expressing alpha fetoprotein, selectively delivering a cytotoxic dose of beta radiation. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Abbreviation:Y90 DOTA MOAB HuAFP31



Previous:yttrium Y 90 anti-CD45 monoclonal antibody AHN-12, yttrium Y 90 anti-CD66 monoclonal antibody BW 250/183, yttrium Y 90 anti-CEA monoclonal antibody cT84.66, yttrium Y 90 daclizumab, yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A
Next:yttrium Y 90 DOTA monoclonal antibody HuPAM4, yttrium Y 90 glass microspheres, yttrium Y 90 humanized epratuzumab, yttrium Y 90 ibritumomab tiuxetan, yttrium Y 90 monoclonal antibody B3

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov